Impact of fast-track regulatory designations on strategic commercialization decisions for autologous cell therapies.
Sign Up to like & getrecommendations! Published in 2022 at "Regenerative medicine"
DOI: 10.2217/rme-2021-0061
Abstract: Background: Regulatory authorities around the world have introduced incentives to improve the speed-to-market of innovative therapies. Aim & methods: To better understand the capacity and portfolio planning decisions of autologous cell therapies and particularly the… read more here.
Keywords: impact fast; decisions autologous; portfolio; fast track ... See more keywords